BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NeurogesX, Inc. (NGSX) Cans 8 of 11 Employees, Looks for Buyer


3/11/2013 9:25:32 AM

NeurogesX Inc. cut eight of its 11 employees and is seeking a buyer for its pain patch Qutenza. Only three executives remain at the San Mateo company (OTCBB: NGSX) — President and CEO Ron Martell, COO Stephen Ghiglieri and Chief Medical Officer Stephen Peroutka — that only a few years ago had more than 100. NeurogesX stock traded for 18 cents per share at the end of Thursday. It had traded as high as $10.60 per share in April 2010 but has been under a dollar since early 2012. The reorganization and potential sale of the company could have a ripple effect, since it cut a deal in 2010 with HealthCare Royalty Partners. NeurogesX received $40 million in exchange for Cowen getting royalties from Qutenza sales in Europe, the Middle East and Africa by partner Astellas Pharma. Cowen was set to get 5 percent of royalties above $90 million until it received a total of $106 million. Although NeurogesX built its own U.S. sales force leading up to Qutenza's April 2010 launch, sales of the roughly $700 pain patch apparently never matched the company's hopes for its highly concentrated synthetic form of capsaicin, the active ingredient in chili pepper. Through the first nine months of last year, NeurogesX recorded revenue of $8.9 million, including $583,000 in U.S. sales in the third quarter, compared with $8.5 million in the same period of 2011.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES